These molecules have been shown to limit disease severity in multiple rodent CVD models, including Ang-II-induced atherosclerosis (Chen et al., 2015), cardiac hypertrophy (Chan et al., 2008), and diabetic cardiomyopathy (Sulaiman et al., 2010). This evidence concerns the gene AGT and cardiac hypertrophy.